Related Experiment Videos
Diffusion of isepamicin into cancellous and cortical bone tissue
1Department of Anesthesiology and Intensive Care, Hĵtel-Dieu Hospital, Lyon, France. emmanuel.boselli@chu-lyon.fr
Journal of Chemotherapy (Florence, Italy)
|November 8, 2002
Summary
Isepamicin effectively penetrates bone tissue at therapeutic concentrations, exceeding the minimum inhibitory concentration for most common bone infection pathogens. This suggests good clinical efficacy for treating bone infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Orthopedics
Background:
- Antibiotic penetration to infection sites is crucial for treating bone and joint infections.
- Understanding isepamicin's bone tissue concentration is vital for assessing its efficacy.
Purpose of the Study:
- To evaluate the bone tissue penetration of isepamicin.
- To correlate isepamicin concentrations with microbiological data for clinical efficacy estimation in bone infections.
Main Methods:
- Open-label, single-arm study involving patients undergoing elective total hip replacement.
- Administered a single parenteral dose of isepamicin (15 mg/Kg).
- Collected plasma and bone samples for high-performance liquid chromatography analysis.
Main Results:
- Mean plasma isepamicin concentration was 43.0 ± 10.4 µg/mL.
- Mean isepamicin concentrations in cancellous and cortical bone were 11.6 ± 7.1 µg/mL and 12.0 ± 7.3 µg/mL, respectively.
- Bone to plasma concentration ratios were 0.28 ± 0.14 (cancellous) and 0.31 ± 0.20 (cortical).
Conclusions:
- Isepamicin bone tissue concentrations exceeded the MIC90 for most susceptible pathogens.
- Achieved concentrations suggest potential clinical efficacy of isepamicin in treating bone infections.
- Further correlation with microbiological data is needed to fully establish clinical efficacy.